Medicare covers continuous glucose monitoring when you have diabetes, meet insulin or hypoglycemia criteria, and your provider prescribes a CGM.
Continuous glucose monitors (CGMs) have moved from niche tools to everyday gear for many people living with diabetes. When you add up device prices, sensors, and transmitters, though, the bill can sting. That is where CMS coverage for continuous glucose monitoring under Medicare makes a real difference. The rules are detailed, but once you break them into plain steps, it gets far easier to see whether you qualify and how to keep coverage in place.
This guide walks through who qualifies, what Medicare pays, and what you need to do so claims keep sailing through. The focus is on people insured through Medicare (Original or Medicare Advantage), since CMS sets the baseline rules those plans follow. You will also see how the newer coverage expansion for non-insulin users with serious lows fits into the picture.
CMS Coverage For Continuous Glucose Monitoring: Quick Overview
CMS Coverage for Continuous Glucose Monitoring now sits inside the Medicare Part B durable medical equipment (DME) benefit. That means CGMs are treated like other medical devices you use at home. Part B pays its share when you meet the clinical rules, your clinician writes an order, and a Medicare-enrolled supplier fills it through the DME channel rather than the pharmacy card in most cases.
In short, you generally need three things for CMS coverage for continuous glucose monitoring:
- A diagnosis of diabetes and a therapeutic CGM that matches its FDA indications.
- Either insulin treatment or a documented history of problematic low blood sugar.
- A recent visit where your clinician evaluates diabetes control and confirms you can use a CGM safely.
The table below sums up the main coverage pieces before we go deeper into each one.
| Requirement | What CMS Expects | What It Means For You |
|---|---|---|
| Diabetes Diagnosis | Documented type 1 or type 2 diabetes in your medical record. | Your chart must clearly show a diabetes diagnosis, not just “high sugar.” |
| Therapeutic CGM Prescription | Device ordered within its FDA indications for use. | The brand and model must be cleared for diabetes management, not wellness only. |
| Insulin Use Or Problematic Hypoglycemia | Insulin treatment of any pattern, or a record of severe or recurrent level 2–3 lows. | You may qualify even without insulin if you have serious lows documented in the record. |
| Recent Evaluation Visit | Visit within six months before the initial order that reviews diabetes control and CGM need. | Medicare wants to see a timely visit tied to the CGM decision, not a note from years ago. |
| Training And Ability To Use CGM | Clinician documents that you or a caregiver can use the CGM as prescribed. | Training can be in-person or virtual; it just needs to be clear in the visit note. |
| Covered Items | CGM receiver or compatible device, sensors, transmitters, and related supplies. | Supplies are billed in 30- or 90-day bundles once coverage is in place. |
| Cost Sharing | Part B deductible, then about 20% coinsurance on the Medicare-approved amount. | Many Medigap plans or Medicaid wrap coverage pick up that 20% share. |
Once you see the pieces laid side by side, the path to coverage becomes clearer: you line up clinical criteria, the right device, and the right paperwork. Next, let’s look at each of those in more detail.
Eligibility Rules For CMS Continuous Glucose Monitoring Coverage
Diabetes Diagnosis And A Prescribed CGM
Medicare coverage starts with a clear diagnosis of diabetes. That can be type 1 or type 2. Your clinician’s notes and problem list need to reflect that diagnosis, not just “hyperglycemia” or “prediabetes.” Claims reviewers look for that signal in the documentation tied to the CGM order.
The CGM itself also matters. Medicare covers therapeutic CGMs that meet the durable medical equipment definition and are used as the main tool for treatment decisions. That includes both “adjunctive” systems, which may still require confirmatory finger sticks in some situations, and “non-adjunctive” systems that can replace routine finger sticks for dosing insulin. The device has to line up with its FDA label; using a sensor in a way that falls outside that label can cause trouble with coverage.
The Medicare.gov page on therapeutic continuous glucose monitors gives a short, plain-language outline of this link between diagnosis, prescription, and device type.
Insulin Treatment Or Problematic Low Blood Sugar
For years, Medicare only covered CGMs for people who used intensive insulin regimens and checked glucose by finger stick many times per day. That older standard shut out many people who still faced serious swings in glucose. In 2023, CMS expanded coverage so that more people qualify.
Current rules recognize two main paths:
- Insulin-treated diabetes: Any pattern of insulin use can count. That includes multiple daily injections, premixed insulin, or insulin through a pump.
- History of problematic hypoglycemia: People who are not on insulin may still qualify if they have documented severe or recurrent level 2 or level 3 low blood sugar episodes.
“Problematic” low blood sugar usually means events that require help from another person, trips to the emergency department, or repeated readings at or below defined low thresholds. The visit note that leads into the CGM order should describe these episodes, how often they happen, and how a CGM is expected to help reduce those events.
The American Diabetes Association has a helpful FAQ on the 2023 Medicare change that widened access to CGMs for people with a history of serious lows, not just those on intensive insulin regimens. You can find that summary in the ADA’s Medicare CGM coverage FAQ.
Visit Timing And Ongoing Follow-Up
CMS wants CGM use to stay tied to active diabetes care, not a one-time order. That is why the coverage rules talk about visit timing. Before your first CGM is ordered under Medicare, you need a visit with the ordering clinician within the previous six months. During that visit, the clinician reviews your diabetes control, documents the criteria you meet (insulin use or problematic hypoglycemia), and confirms that a CGM is clinically reasonable.
After you start therapy, Medicare expects follow-up visits roughly every six months. Those visits should document that you are using the CGM, that the readings are shaping treatment decisions, and that the device still makes sense for your situation. If long gaps appear between visits or the notes never mention the CGM again, suppliers may run into denials when they bill for ongoing sensors and supplies.
This follow-up rhythm helps keep coverage aligned with real-world use. It also gives you regular time with your care team to look at trends and fine-tune your plan.
What Medicare Pays For Continuous Glucose Monitoring
Once you meet the clinical criteria, the next question is money. CMS Coverage for Continuous Glucose Monitoring falls under the Part B DME benefit. That shapes which items are covered, how often they can ship, and how much lands on your bill each month.
CGM As Durable Medical Equipment Under Part B
Under Part B, a therapeutic CGM is treated much like a home blood glucose monitor, but with a different billing code set and different supply bundles. Medicare covers the reader or receiver (when one is used), the transmitter when the system uses a separate transmitter piece, and the disposable sensors that you apply to the skin.
To qualify as DME under CMS rules, the device must be used repeatedly, serve a medical purpose, and be appropriate for use in the home. That is why wellness-only sensors marketed to people without diabetes do not qualify under the same benefit. When in doubt about a specific brand or model, your supplier can check whether it sits on the list of covered CGM systems for Medicare.
CGM Supplies, Sensors, And Billing Cycles
After the first CGM shipment, supplies typically go out in recurring bundles. Sensors may be billed every 30 or 90 days, depending on both the device and the supplier’s setup. CMS added the 90-day option for some CGM supply codes, which can reduce paperwork for everyone involved.
Each supply shipment has a maximum quantity tied to how long a sensor is meant to last. For instance, a 14-day sensor will be allowed in smaller numbers per month than a seven-day sensor. Billing staff must match your device to the correct code and frequency; when they get that match wrong, claims may deny even though you meet the clinical rules.
People often worry about what happens when a sensor falls off early or fails. Most CGM makers have replacement policies for defective sensors, and those replacements often come through the manufacturer rather than as new Medicare claims. Your supplier or device maker can walk you through their replacement process.
What You Pay Under Different Medicare Setups
Under Original Medicare, Part B pays 80% of the Medicare-approved amount once you meet the yearly Part B deductible. You pay the remaining 20% coinsurance. If you have a Medigap (Medicare Supplement) plan, that plan may pay some or all of the 20% share, depending on which letter plan you carry.
Medicare Advantage plans must offer at least the same overall coverage as Original Medicare, but they can use their own supplier networks, prior authorization steps, and cost-sharing structures. Some charge flat copays for CGM supplies, while others mirror the 20% structure. Plan documents spell out those details, and many plans post them in an online portal where you can see DME copays and coinsurance.
The table below gives ballpark patterns rather than exact dollar numbers. Actual costs depend on the device brand, supplier contracts, your plan type, and whether any secondary coverage is in place.
| Coverage Situation | Typical CGM Cost Share | What Helps Reduce Bills |
|---|---|---|
| Original Medicare Only | Part B deductible, then around 20% of the approved amount. | Use suppliers that accept assignment so you avoid extra balance bills. |
| Original Medicare + Medigap | Many Medigap plans pay most or all of the 20% share. | Check your Medigap letter plan chart to see how it handles Part B coinsurance. |
| Medicare Advantage Plan | Copay or percentage set by the plan’s DME benefit. | Stay in-network and watch for prior authorization steps before ordering. |
| Medicare + Medicaid (Dual Eligible) | Medicaid often covers the Part B coinsurance after Medicare pays. | Work with suppliers who can bill both programs correctly. |
| No Qualifying Criteria Met | CGM not covered under the Medicare DME benefit. | Talk with your clinician about whether your history now meets the current low-glucose criteria. |
| Wellness-Only CGM Use | Not covered; Medicare does not pay for non-medical use. | Coverage requires a diabetes diagnosis and clinical need, not general wellness tracking. |
| Supplier Not Enrolled In Medicare | Claims may deny or pay only a limited amount. | Ask suppliers upfront whether they are Medicare-enrolled and accept assignment. |
These patterns give a sense of how much CGM therapy might cost from month to month. For a personal estimate, you can call your plan or supplier with your exact device and coverage details.
Steps To Get Your CGM Approved Under CMS Rules
Knowing the rules is one thing; getting through the paperwork is another. Here are practical steps that line up with current CMS coverage for continuous glucose monitoring and help keep orders moving smoothly.
Start With A Targeted Diabetes Visit
Book a visit that focuses directly on your glucose patterns, current treatment, and CGM goals. Bring recent glucose logs, meter downloads, or app reports. Be ready to describe low blood sugar episodes, including how often they happen and whether you needed help from someone else or urgent care.
During this visit, your clinician can document your diabetes type, insulin regimen if you use insulin, and any history of problematic lows. They can also note why a CGM is reasonable for you now, such as night-time lows, wide swings in glucose, or fear of driving with unrecognized lows. That single note often serves as the anchor for the initial Medicare CGM order.
Work With A Medicare-Enrolled Supplier
Next, your clinician sends the order and supporting records to a DME supplier that handles Medicare CGM claims. The supplier checks that all required elements are present: diagnosis codes, visit date, device brand and model, and clinical criteria. Some suppliers call you to review your coverage and explain cost-sharing before they ship anything.
If you have a Medicare Advantage plan, the supplier may also handle any prior authorization request. That process can involve sending chart notes and answering plan questions about why a CGM is needed. Staying with a supplier that knows Medicare CGM rules well can spare you from repeat denials based on missing documents.
Stay On Top Of Refills And Follow-Up Visits
After your first shipment, set reminders for both sensor refills and follow-up visits. Many sensors last 10 to 14 days; transmitters may last several months. Suppliers usually reach out when it is time for the next bundle, but it helps to track your own timeline.
As you near the six-month mark after your first order, schedule another diabetes visit. Bring CGM reports from the device app or receiver. During that visit, your clinician can show how CGM data has shaped insulin adjustments or other changes and confirm that you are still using the device. That simple pattern of visit, documentation, and refill helps keep coverage stable year after year.
Final Thoughts On CMS CGM Coverage
CMS Coverage for Continuous Glucose Monitoring has opened the door for many more people living with diabetes to use sensors every day instead of relying only on finger sticks. The rules still ask for clear documentation and regular follow-up, but they no longer limit coverage only to people on the most intensive insulin regimens.
If you have diabetes and either use insulin or live with repeated low blood sugar episodes, it is worth asking whether you fit the current Medicare criteria. A short, focused visit, the right device, and a Medicare-savvy supplier can turn a dense policy into a workable, real-world plan for round-the-clock glucose data.